GLP-1 Receptor Agonists for Weight Loss

Introduction to GLP-1 Receptor Agonists

The American College of Cardiology recommends GLP-1 receptor agonists, such as semaglutide, liraglutide, and tirzepatide, for weight loss in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, with tirzepatide demonstrating superior efficacy (20.9% weight loss) compared to semaglutide (14.9%) and liraglutide (6.1-17.4%) 1

The FDA approved semaglutide 2.4mg weekly for chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnea, with a mean weight loss of 14.9% at 68 weeks 1, 2
The FDA approved liraglutide 3.0mg daily for weight management in adults with BMI >30 kg/m² or >27 kg/m² with weight-related comorbidities, with a mean weight loss of 6.1-17.4% 1, 2, 3
The FDA approved tirzepatide 15mg weekly for obesity treatment in adults with BMI ≥30 kg/m² or ≥27 kg/m² with one or more obesity-associated comorbid conditions, with a mean weight loss of 20.9% compared to semaglutide's 14.9% 1

The American Medical Association recommends insurance coverage for GLP-1 receptor agonists, such as semaglutide, liraglutide, and tirzepatide, for adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnea 1, 2, 3
Patients must demonstrate inadequate response to lifestyle interventions alone (diet, physical activity, behavioral modifications) before approval, with insurance typically requiring 3-6 months of documented lifestyle modification attempts with insufficient weight loss 3

The Endocrine Society recommends prioritizing tirzepatide as the first-line choice due to its greatest weight loss (20.9%) and superior cardiometabolic benefits, with semaglutide 2.4mg as the second-line choice if tirzepatide is unavailable or not tolerated 1
Liraglutide 3.0mg daily is recommended as the third-line choice when weekly injections are not feasible or patient preference for daily dosing, with lower efficacy compared to semaglutide and tirzepatide 1, 3

The American Association of Clinical Endocrinologists recommends a gradual dose titration of semaglutide, starting at 0.25mg weekly for 4 weeks, increasing to 0.5mg weekly for 4 weeks, and eventually reaching a maintenance dose of 2.4mg weekly after 16 weeks 1
The American Diabetes Association recommends a similar titration schedule for liraglutide, starting at 0.6mg subcutaneous daily for 1 week, increasing by 0.6mg weekly until reaching the target dose of 3.0mg daily 3
The FDA-approved starting dose of tirzepatide is 5mg weekly, with titration up to 10mg or 15mg weekly based on response and tolerability 1

The American College of Cardiology recommends that all three medications are contraindicated in patients with a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia syndrome type 2 1, 3

The Endocrine Society recommends monitoring blood pressure, signs and symptoms of pancreatitis, gallbladder disease symptoms, nutritional status, and thyroid function during treatment with GLP-1 receptor agonists 1, 3

The American Diabetes Association recommends that patients with type 2 diabetes prioritize tirzepatide or semaglutide 2.4mg over lower-dose semaglutide due to greater HbA1c reduction, with weight loss appearing lower in individuals with type 2 diabetes (4-6.2%) compared to those without diabetes (6.1-17.4%) 1
The American Heart Association recommends considering cardiovascular disease status when selecting between medications, with semaglutide 2.4mg having proven cardiovascular benefit in patients with obesity and established CVD 1

The American Medical Association recommends that patients be counseled that these medications need to be used lifelong in conjunction with lifestyle changes, with significant weight regain occurring after cessation of semaglutide (11.6% of lost weight regained after 52 weeks) 1
The Academy of Nutrition and Dietetics recommends combining GLP-1 receptor agonists with reduced-calorie diet and increased physical activity, including resistance training, for optimal results and to preserve lean body mass 1

The American Heart Association acknowledges that semaglutide 2.4mg reduces the composite risk of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (HR 0.80) in patients with obesity and established cardiovascular disease 4